@article{27465f85a3384923be3bfff9c08c2d03,
title = "Preventing antimalarial drug resistance with triple artemisinin-based combination therapies",
abstract = "Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance. Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use. We show that introduction of TACTs could significantly delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs, and improving the chances of malaria elimination. We conclude that immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance.",
author = "Nguyen, {Tran Dang} and Bo Gao and Chanaki Amaratunga and Mehul Dhorda and Tran, {Thu Nguyen-Anh} and White, {Nicholas J.} and Dondorp, {Arjen M.} and Boni, {Maciej F.} and Ricardo Aguas",
note = "Funding Information: This research falls under the auspices of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project funded by UK Aid and the UK Government{\textquoteright}s Foreign, Commonwealth, and Development Office. We would like to thank all project collaborators for their valuable contribution to project planning and rollout and/or for all the inputs that eventually led to the hypotheses tested in this manuscript. The authors also acknowledge the following sources of funding: UK Aid and the UK Government{\textquoteright}s Foreign, Commonwealth, and Development Office (C.A., M.D., A.D., N.J.W.). Wellcome Trust grant 220211 (C.A., M.D., A.D., N.J.W.). National Institutes of Health grant NIAID R01AI153355 (M.F.B., T.D.N., T.N.-A.T.). The Bill and Melinda Gates Foundation INV-005517 grant was awarded to Pennsylvania State University (M.F.B., T.D.N., T.N.-A.T.). Bill and Melinda Gates Foundation grant OPP1193472 (R.A.). Funding Information: This research falls under the auspices of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project funded by UK Aid and the UK Government{\textquoteright}s Foreign, Commonwealth, and Development Office. We would like to thank all project collaborators for their valuable contribution to project planning and rollout and/or for all the inputs that eventually led to the hypotheses tested in this manuscript. The authors also acknowledge the following sources of funding: UK Aid and the UK Government{\textquoteright}s Foreign, Commonwealth, and Development Office (C.A., M.D., A.D., N.J.W.). Wellcome Trust grant 220211 (C.A., M.D., A.D., N.J.W.). National Institutes of Health grant NIAID R01AI153355 (M.F.B., T.D.N., T.N.-A.T.). The Bill and Melinda Gates Foundation INV-005517 grant was awarded to Pennsylvania State University (M.F.B., T.D.N., T.N.-A.T.). Bill and Melinda Gates Foundation grant OPP1193472 (R.A.). Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = dec,
doi = "https://doi.org/10.1038/s41467-023-39914-3",
language = "English",
volume = "14",
pages = "4568",
journal = "Nature communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}